The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
The Japanese Patent Office has issued a favorable Appeal Decision granting a patent for the use of REQORSA Gene Therapy in combination with PD-L1 antibodies to treat cancer
Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
Till 30th November 2024, more than 2690 PACS have been given initial approval and 687 Kendras have been opened in PACS
Akums Drugs will undertake this development and commercialization in India
Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
Subscribe To Our Newsletter & Stay Updated
